These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9386990)

  • 1. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor.
    Dougher AM; Wasserstrom H; Torley L; Shridaran L; Westdock P; Hileman RE; Fromm JR; Anderberg R; Lyman S; Linhardt RJ; Kaplan J; Terman BI
    Growth Factors; 1997; 14(4):257-68. PubMed ID: 9386990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a soluble vascular endothelial growth factor receptor-immunoglobulin chimera.
    Kaplan JB; Sridharan L; Zaccardi JA; Dougher-Vermazen M; Terman BI
    Growth Factors; 1997; 14(4):243-56. PubMed ID: 9386989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.
    Gengrinovitch S; Greenberg SM; Cohen T; Gitay-Goren H; Rockwell P; Maione TE; Levi BZ; Neufeld G
    J Biol Chem; 1995 Jun; 270(25):15059-65. PubMed ID: 7797488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective binding of VEGF121 to one of the three vascular endothelial growth factor receptors of vascular endothelial cells.
    Gitay-Goren H; Cohen T; Tessler S; Soker S; Gengrinovitch S; Rockwell P; Klagsbrun M; Levi BZ; Neufeld G
    J Biol Chem; 1996 Mar; 271(10):5519-23. PubMed ID: 8621410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain.
    Soker S; Fidder H; Neufeld G; Klagsbrun M
    J Biol Chem; 1996 Mar; 271(10):5761-7. PubMed ID: 8621443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling.
    Tao Q; Backer MV; Backer JM; Terman BI
    J Biol Chem; 2001 Jun; 276(24):21916-23. PubMed ID: 11399777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells.
    Cohen T; Gitay-Goren H; Sharon R; Shibuya M; Halaban R; Levi BZ; Neufeld G
    J Biol Chem; 1995 May; 270(19):11322-6. PubMed ID: 7744769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors.
    Tessler S; Rockwell P; Hicklin D; Cohen T; Levi BZ; Witte L; Lemischka IR; Neufeld G
    J Biol Chem; 1994 Apr; 269(17):12456-61. PubMed ID: 8175651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis.
    Keyt BA; Nguyen HV; Berleau LT; Duarte CM; Park J; Chen H; Ferrara N
    J Biol Chem; 1996 Mar; 271(10):5638-46. PubMed ID: 8621427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
    Park JE; Chen HH; Winer J; Houck KA; Ferrara N
    J Biol Chem; 1994 Oct; 269(41):25646-54. PubMed ID: 7929268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency.
    Keyt BA; Berleau LT; Nguyen HV; Chen H; Heinsohn H; Vandlen R; Ferrara N
    J Biol Chem; 1996 Mar; 271(13):7788-95. PubMed ID: 8631822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165.
    Soker S; Gollamudi-Payne S; Fidder H; Charmahelli H; Klagsbrun M
    J Biol Chem; 1997 Dec; 272(50):31582-8. PubMed ID: 9395496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis.
    Binétruy-Tournaire R; Demangel C; Malavaud B; Vassy R; Rouyre S; Kraemer M; Plouët J; Derbin C; Perret G; Mazié JC
    EMBO J; 2000 Apr; 19(7):1525-33. PubMed ID: 10747021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased vascular endothelial growth factor 165 binding to kinase insert domain-containing receptor after infection of human endothelial cells by recombinant adenovirus encoding the Vegf(165) gene.
    Weisz A; Koren B; Cohen T; Neufeld G; Kleinberger T; Lewis BS; Flugelman MY
    Circulation; 2001 Apr; 103(14):1887-92. PubMed ID: 11294808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variations in the size and sulfation of heparin modulate the effect of heparin on the binding of VEGF165 to its receptors.
    Soker S; Goldstaub D; Svahn CM; Vlodavsky I; Levi BZ; Neufeld G
    Biochem Biophys Res Commun; 1994 Sep; 203(2):1339-47. PubMed ID: 7522446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.
    Soker S; Takashima S; Miao HQ; Neufeld G; Klagsbrun M
    Cell; 1998 Mar; 92(6):735-45. PubMed ID: 9529250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR.
    Cao Y; Chen H; Zhou L; Chiang MK; Anand-Apte B; Weatherbee JA; Wang Y; Fang F; Flanagan JG; Tsang ML
    J Biol Chem; 1996 Feb; 271(6):3154-62. PubMed ID: 8621715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF.
    Piossek C; Schneider-Mergener J; Schirner M; Vakalopoulou E; Germeroth L; Thierauch KH
    J Biol Chem; 1999 Feb; 274(9):5612-9. PubMed ID: 10026178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding.
    Soker S; Miao HQ; Nomi M; Takashima S; Klagsbrun M
    J Cell Biochem; 2002; 85(2):357-68. PubMed ID: 11948691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential binding characteristics and cellular inhibition by soluble VEGF receptors 1 and 2.
    Roeckl W; Hecht D; Sztajer H; Waltenberger J; Yayon A; Weich HA
    Exp Cell Res; 1998 May; 241(1):161-70. PubMed ID: 9633524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.